DHR
Danaher Corporation (NYSE: DHR) reported better-than-expected results for the second quarter 2026, with...
Article Summary
BUY- Danaher Corporation (NYSE: DHR) reported better-than-expected results for the second quarter 2026, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth.
- Life Sciences businesses delivered their strongest quarter in several years, while customer project timing impacted bioprocessing revenue, but underlying order trends remained strong and biobiocessing orders grew mid-teens in the quarter.
- Danaher expects full-year core revenue to increase in the 3.0-4.0% range year-over-year, with adjusted diluted net earnings increasing to $8.45-8.9 billion.
- Full-year guidance does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin, or adjusted diluted earnings per share to GAAP because additional elements such as future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments, and the outcome of legal proceedings are difficult to predict and estimate.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 4.0% | 25% | 20.0 ptsMinimal (4.0%) - Very weak |
| EPS Growth Next 5Y ? | 8.5% | 25% | 20.0 ptsWeak (8.5%) - Low expectations |
| Target Price Upside ? | 39.5% | 20% | 85.0 ptsLarge Upside (39.5%) - Target: $241.27 vs Current: $173.00 |
| Gross Margin % ? | 61.1% | 15% | 80.0 ptsVery Healthy (61.1%) - High-quality margins |
| Drawdown from 52-Wk High ? | -28.8% | 15% | 80.0 ptsSolid Dip (-28.8%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DHR
- Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
- The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
- The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
- The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.
- The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
- The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
- Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.